Page last updated: 2024-09-04

lonafarnib and daunorubicin

lonafarnib has been researched along with daunorubicin in 2 studies

Compound Research Comparison

Studies (lonafarnib)	Trials (lonafarnib)	Recent Studies (post-2010) (lonafarnib)	Studies (daunorubicin)	Trials (daunorubicin)	Recent Studies (post-2010) (daunorubicin)
224	34	90	8,239	886	1,310

Protein Interaction Comparison

Protein	Taxonomy	daunorubicin (IC50)
72 kDa type IV collagenase	Homo sapiens (human)	1.9
Multidrug resistance-associated protein 1	Homo sapiens (human)	8
Histone deacetylase 1	Homo sapiens (human)	0.047
Histone deacetylase 8	Homo sapiens (human)	0.22
Histone deacetylase 6	Homo sapiens (human)	0.02

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Casciano, CN; Clement, RP; Johnson, WW; Wang, E	1
Bishop, WR; Nakajima, A; Ohyashiki, K; Sumi, M; Tauchi, T	1

Other Studies

2 other study(ies) available for lonafarnib and daunorubicin

Article	Year
The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer research, 2001, Oct-15, Volume: 61, Issue:20 Topics: 3T3 Cells; Adenosine Triphosphate; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Cell Line; CHO Cells; Cricetinae; Daunorubicin; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Genes, MDR; Humans; Hydrolysis; Mice; Paclitaxel; Piperidines; Pyridines; Rhodamine 123; Tamoxifen; Vinblastine	2001
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Molecular cancer therapeutics, 2003, Volume: 2, Issue:3 Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Transfection; Treatment Outcome; Tumor Cells, Cultured	2003

Article

Year

The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.

Cancer research, 2001, Oct-15, Volume: 61, Issue:20

Topics: 3T3 Cells; Adenosine Triphosphate; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Cell Line; CHO Cells; Cricetinae; Daunorubicin; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Genes, MDR; Humans; Hydrolysis; Mice; Paclitaxel; Piperidines; Pyridines; Rhodamine 123; Tamoxifen; Vinblastine

2001

Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.

Molecular cancer therapeutics, 2003, Volume: 2, Issue:3

Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Transfection; Treatment Outcome; Tumor Cells, Cultured

2003